EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

Andrea De Vito iD, Andrea Marongiu, Antonella Cano, Mariangela Puci, Agnese Colpani, Susanna Maria Nuvoli, Maria Grazia Catte, Giulia Moi, Maria Antonietta Deledda, Sergio Uzzau, Giovanni Sotgiu, Franca Deriu und 2 weitere

HIV Medicine · 2026-05 · 27 (5) · 727-739

DOI: 10.1111/hiv.70202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, online erschienen am 28.01.2026. Verfasst von Andrea De Vito und 13 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Infectious Diseases, Department of Medicine, Surgery, and Pharmacy, University of Sassari, Sassari, Italy. Hauptthemen laut MEDLINE: Body Composition, HIV Infections, Rilpivirine, Pyridones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.

Methods

We conducted a prospective cohort study involving 29 people with HIV initiating CAB + RPV LA at a single centre in Italy. Body composition was assessed using dual‐energy X‐ray absorptiometry (DXA) and bioelectrical impedance analysis (BIA) at baseline, 24 and 48 weeks. Anthropometrics, laboratory parameters and patient‐reported outcomes were also collected. Statistical comparisons across time points were performed using paired tests ( p < 0.05 considered significant).

Results

At 48 weeks, weight and BMI remained stable. Waist circumference significantly decreased (median 97 (IQR 91–102) to 94 (IQR 89–98) cm, p = 0.026), with no significant change in total fat percentage or visceral adipose tissue. A modest but statistically significant increase in trunk/limb fat ratio (mean 1.19 (SD 0.39) to 1.25 (SD 0.41), p = 0.035). Lean mass and muscle function were unchanged. BIA findings confirmed stable fat mass and body water compartments. Virologic suppression was maintained in all participants throughout follow‐up. High‐density lipoprotein (HDL) cholesterol increased significantly, accompanied by a rise in total cholesterol, while low‐density lipoprotein (LDL) cholesterol, triglycerides and the total cholesterol/HDL ratio remained stable. Serum creatinine significantly decreased, mainly among individuals switching from bictegravir‐ or dolutegravir‐based regimens. Glycaemia, insulin, HOMA‐IR, Metabolic Score for Insulin Resistance (METS‐IR), liver enzymes and hepatic steatosis and fibrosis indices remained stable. Adverse events, mostly injection‐site reactions, decreased over time. Only one participant discontinued treatment. Treatment satisfaction improved throughout the study.

Conclusion

CAB + RPV LA was not associated with significant weight gain, clinically relevant changes in body composition or adverse metabolic effects over 48 weeks. Virologic suppression was maintained, renal laboratory parameters improved in prior INSTI users and treatment was well tolerated with increasing satisfaction. These findings support CAB + RPV LA as a safe, effective and metabolically neutral alternative to daily oral ART.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Body CompositionHIV InfectionsRilpivirinePyridonesWeight GainAnti-HIV AgentsQuality of LifeHumansFemaleMaleMiddle AgedProspective StudiesAdultAbsorptiometry, PhotonItalyDiketopiperazines

Stichwörter der Autor:innen

CabotegravirHIVRilpivirineantiretroviral therapybioelectrical impedance analysisbody compositiondual‐energy X‐ray absorptiometrylong‐acting injectablesmetabolic changes

Substanzen

RilpivirinePyridonesAnti-HIV AgentscabotegravirDiketopiperazines

Autor:innen und Institutionen

  • Unit of Infectious Diseases, Department of Medicine, Surgery, and Pharmacy, University of Sassari, Sassari, Italy.
  • PhD School in Biomedical Science, Biomedical Science Department, University of Sassari, Sassari, Italy.
  • Unit of Nuclear Medicine, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.
  • Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
  • University Hospital of Sassari, Sassari (AOUSS), Sassari, Italy.
  • Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.

ORCID-Profile: Andrea De Vito

Zitieren

APA

De Vito, A., Marongiu, A., Cano, A., Puci, M., Colpani, A., Nuvoli, S. M., Catte, M. G., Moi, G., Deledda, M. A., Uzzau, S., Sotgiu, G., Deriu, F., Spanu, A., & Madeddu, G. (2026). Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV. HIV Medicine, 27(5), 727-739. https://doi.org/10.1111/hiv.70202

Vancouver

De Vito A, Marongiu A, Cano A, Puci M, Colpani A, Nuvoli SM, et al. Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV. HIV Medicine. 2026;27(5):727-739. doi:10.1111/hiv.70202

BibTeX
@article{DeVito2026,
  author = {De Vito, Andrea and Marongiu, Andrea and Cano, Antonella and Puci, Mariangela and Colpani, Agnese and Nuvoli, Susanna Maria and Catte, Maria Grazia and Moi, Giulia and Deledda, Maria Antonietta and Uzzau, Sergio and Sotgiu, Giovanni and Deriu, Franca and Spanu, Angela and Madeddu, Giordano},
  title = {Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV},
  journal = {HIV Medicine},
  year = {2026},
  volume = {27},
  number = {5},
  pages = {727--739},
  doi = {10.1111/hiv.70202}
}
Kostenlos starten →